MARKET

JAZZ

JAZZ

Jazz Pharmaceuticals Plc
NASDAQ
128.45
+0.03
+0.02%
After Hours: 128.40 -0.05 -0.04% 17:58 02/22 EST
OPEN
128.42
PREV CLOSE
128.42
HIGH
128.63
LOW
126.09
VOLUME
343.44K
TURNOVER
0
52 WEEK HIGH
147.98
52 WEEK LOW
111.25
MARKET CAP
8.09B
P/E (TTM)
212.91
1D
5D
1M
3M
1Y
5Y
Ardelyx (ARDX) Reports Q4 Loss, Lags Revenue Estimates
NASDAQ · 8h ago
Axsome (AXSM) Stock Falls Despite Q4 Earnings & Revenue Beat
NASDAQ · 1d ago
Jazz Pharmaceuticals names Philip Johnson as CFO
Seeking Alpha · 1d ago
Jazz Pharmaceuticals Welcomes New CFO with Strong Financial Expertise
TipRanks · 1d ago
Jazz Pharma Names Eli Lilly's Philip Johnson CFO, Effective March 1
NASDAQ · 1d ago
Jazz Pharma Taps Philip Johnson as CFO Effective March 1, 2024 Taking Over from Renée Galá
Benzinga · 1d ago
Weekly Report: what happened at JAZZ last week (0212-0216)?
Weekly Report · 3d ago
Is Jazz Pharmaceuticals (NASDAQ:JAZZ) A Risky Investment?
Jazz Pharmaceuticals plc had US$5.72b in debt in September 2023. The company's balance sheet is a good place to look at to see if debt is making the company risky. Debt can be a good tool for businesses that need to invest in growth. Jazz Pharmaceuticals's net debt is 2.5 times its EBITDA, but the company is able to cover its interest with free cash flow. The firm has a strong balance sheet and is in a good position to manage its debt levels.
Simply Wall St · 4d ago
More
About JAZZ
Jazz Pharmaceuticals PLC is a biotechnology company. The Company is engaged in developing medicines for people with serious diseases. The Company’s lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Defitelio (defibrotide sodium) AND Vyxeos (daunorubicin and cytarabine) liposome for injection. The Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution product is for the treatment of cataplexy or excessive daytime sleepiness (EDS), in patients with narcolepsy seven years of age and older. The Xyrem (sodium oxybate) oral solution product is for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older. The Defitelio (defibrotide sodium) product is for the treatment of hepatic veno-occlusive disease (VOD).

Webull offers Jazz Pharmaceuticals PLC stock information, including NASDAQ: JAZZ real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JAZZ stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading JAZZ stock methods without spending real money on the virtual paper trading platform.